July 24th, 2011
APPRAISE-2 Dashes Hope of Adding Anticoagulant to Antiplatelet Therapy in ACS
Larry Husten, PHD
A large phase 3 trial of an investigational factor Xa inhibitor, when added to antiplatelet therapy in ACS patients, was stopped early because of bleeding complications.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?